Sandoz has revealed plans to invest at least $400m to build a new biologics production plant in Lendava, Slovenia, after signing a memorandum of understanding for what has been described as one of the largest ever international private-sector investments in the country. Work on the facility is set to begin this year, with full operations at the plant “provisionally” planned for late 2026.
Sandoz Unveils $400m+ Investment In Slovenian Biosimilars Plant
Lendava Biologics Facility Is Expected To Become Fully Operational By 2026
Spurred on by “increasing global demand for biosimilar medicines,” Sandoz has revealed plans to invest at least $400m in building a new biologics production plant in Slovenia.
More from Manufacturing
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
• By
Along with financial backing from the Canadian government, a fresh, decade-long partnership with Sandoz Canada will allow Delpharm to carry out modernization plans for its manufacturing facility in Boucherville, securing the local supply chain for sterile injectable medicines.
• By
Biocon Biologics is partnering with Civica to supply insulin aspart drug substance that will be used for final US manufacturing by Civica at its plant in Petersburg, Virginia.
• By
Viatris anticipates that half-a-billion dollars will disappear from its top line in 2025 on the back of the recent import alert for its oral solids facility in Indore, with much of the pain being caused by the firm’s failure to have its generic version of Revlimid exempt from the restrictions.